Antineoplastic drugs : organic synthesis / / Daniel Lednicer

• Record Nr.: UNINA9910131339603321
• Autore: Lednicer Daniel
• Pubbl/distr/stampa: Chichester, England : , : Wiley, , 2015; ©2015
• ISBN: 1-118-89256-9; 1-118-89255-0; 1-118-89257-7
• Descrizione fisica: 1 online resource (230 p.)
• Classificazione: SCI007000
• Disciplina: 616.994061
• Soggetti: Antineoplastic agents
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references at the end of each chapters and indexes.
• Nota di contenuto: Title Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction; 3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References; Chapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly ; Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates; 7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors; 9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA
• Sommario/riassunto: "Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations"--